Citizens Financial Group’s equity research unit cut its price target on medical robotics company Stereotaxis Inc. to $3 from $4, maintaining a market outperform rating amid weaker-than-expected guidance and a revenue shortfall.
The adjustment follows Stereotaxis’s fiscal second-quarter results for 2026, which reported revenue of $7.7 million, below the $8.68 million forecast by Wall Street. The company’s adjusted loss per share matched estimates at $0.05. Stereotaxis also lowered its full-year guidance, reflecting a more conservative outlook tied to system placements.
Shares of Stereotaxis closed at $1.45 on Wednesday, up 2.84% on the session, bringing the year-to-date decline to 37% and the 12-month loss to 50%. The stock has yet to achieve profitability, posting a trailing 12-month loss of $0.24 per share, with analysts not anticipating earnings for the current year.
Despite the operational challenges, Stereotaxis highlighted progress in its robotic catheter and digital surgery product lines, noting growing market traction. Citizens’ decision to reduce the price target underscores concerns over near-term revenue growth and execution risks, even as the firm retains a positive long-term view on the company’s technology platform.
The revised target implies a potential upside of approximately 107% from current levels, though execution risks remain elevated given the company’s financial trajectory and competitive dynamics in the medical robotics sector.
